1. Home
  2. HOUR vs CTSO Comparison

HOUR vs CTSO Comparison

Compare HOUR & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hour Loop Inc.

HOUR

Hour Loop Inc.

N/A

Current Price

$1.91

Market Cap

63.3M

ML Signal

N/A

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

N/A

Current Price

$0.77

Market Cap

45.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HOUR
CTSO
Founded
2015
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.3M
45.7M
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
HOUR
CTSO
Price
$1.91
$0.77
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.38
AVG Volume (30 Days)
10.8K
67.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
128.57
N/A
EPS
0.07
N/A
Revenue
$138,252,861.00
$22,503,908.00
Revenue This Year
N/A
$7.29
Revenue Next Year
N/A
$8.91
P/E Ratio
$27.40
N/A
Revenue Growth
4.64
48.53
52 Week Low
$1.10
$0.60
52 Week High
$6.84
$1.39

Technical Indicators

Market Signals
Indicator
HOUR
CTSO
Relative Strength Index (RSI) 51.83 54.78
Support Level $1.74 $0.62
Resistance Level $1.95 $0.84
Average True Range (ATR) 0.04 0.04
MACD -0.00 0.01
Stochastic Oscillator 9.09 59.46

Price Performance

Historical Comparison
HOUR
CTSO

About HOUR Hour Loop Inc.

Hour Loop Inc is a technology-enabled consumer products company that uses machine learning and data analytics to design, develop, market, and sell products. Hour Loop predominantly operates through online retail channels such as Amazon, Walmart, and Hourloop.com. The Company, as an Internet marketplace seller, sells products in multiple categories, including home/garden decor, toys, kitchenware, apparel, and electronics. It has only one segment, which is online retail (e-commerce).

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: